Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple blood marker may reveal hidden heart risks in lupus

NCT ID NCT07719322

Knowledge-focused Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study investigates whether the triglyceride-glucose (TyG) index, a simple blood-based measure of insulin resistance, can predict early signs of atherosclerosis in people with lupus nephritis. Researchers will measure carotid artery thickness and plaque in 156 adults with lupus, with or without kidney involvement, and compare it to their TyG index. The goal is to see if this inexpensive test could help catch cardiovascular risk early, before heart problems develop.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the TyG index proves reliable, it could offer a simple, non-invasive way to identify lupus patients at high cardiovascular risk before symptoms appear.
What could go wrong
This is an observational study, not a treatment trial. It may show a correlation but cannot prove cause, and results may not apply to all lupus patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 156 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged ≥18 years Diagnosed as SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus including patients with and without Lupus nephritis recruited from Assiut University Hospital,Internal medicine departement, ,Rheumatology and Renal unit(inpatient,\_outpatient clinics)

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years * Diagnosis of SLE according to the 2019 ACR/EULAR classification criteria for systemic lupus erythematosus. * Lupus nephritis , classified according to the 2018 ISN/RPS classification of lupus nephritis. Exclusion Criteria: * Established cardiovascular disease (MI, stroke, PAD) * Diabetes mellitus * Hypertension * Patient with CKD * infections * other autoimmune diseases * Pregnancy * Malignancy * chronic liver disease * Dyslipidemia * Obesity * Patients on lipid lowering therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lupus nephritis (LN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lupus nephritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lupus nephritis (LN) Systemic lupus erthematosus (SLE)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Assuit university hospitals

    Asyut, Assuit, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.